the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis
Ulcerative Colitis
About this trial
This is an interventional treatment trial for Ulcerative Colitis
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old. Both male and female sex. Newly diagnosed patients with mild and moderate ulcerative colitis and treated with 5-aminosalicylic acid (mesalamine). Exclusion Criteria: Patients with severe ulcerative colitis. Patients with colorectal cancer. Patients on rectal or systemic steroids. Patients on immunosuppressants or biological therapies. Patients with previously failed treatment with sulphasalazine. Patients with known allergy to study medications. History of complete or partial colectomy. Patients with heart diseases and arrhythmia. Patients on blood thinning agents. Patients on anticoagulants (warfarin), anticonvulsants (carbamazepine and phenytoin), muscle relaxants (chlorzoxazone) and non-steroidal anti-inflammatory drugs (diclofenac).
Sites / Locations
- Tanta university hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
control group
diosmin group
Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.
Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months.